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Abstract
Background: In the Middle East and North Africa (MENA), hepatitis C virus (HCV) distribution appears to present a
wide range of prevalence. The scale and nature of HCV disease burden is poorly known in the Horn of Africa sub-region
of MENA including Djibouti, Somalia, and Sudan in addition to Yemen at the southwest corner of the Arabian Peninsula.
The aim of this review is to provide a systematic review and synthesis of all epidemiological data on HCV prevalence
and incidence among the different population groups in this sub-region of MENA. A second aim of the study is to
estimate the national population-level HCV prevalence for each of these four countries.
Methods/design: The systematic review will be conducted based on the items outlined in the PRISMA
statement. PubMed, Embase, and the World Health organization (WHO) regional databases will be searched for
eligible studies without language or date restrictions. Observational and intervention studies reporting data on
the prevalence or incidence of HCV in any population group in Djibouti, Somalia, Sudan, or Yemen will be
included. Additional sources will be obtained through the database of the MENA HIV/AIDS Epidemiology
Synthesis Project, including international organizations’ reports and country-level reports, and abstracts of international
conferences. Study and population characteristics will be extracted from eligible publications, with previously agreed pro
formas; and entered into a computerized database. We will pool prevalence using DerSimonian and Laird random-effects
models after a Freeman-Tukey transformation to stabilize variances. We will conduct meta-regression analysis to explore
the effect of study-level characteristics as potential sources of heterogeneity.
Discussion: This proposed systematic review and meta-analysis aims to better describe HCV infection distribution across
countries in the Horn of Africa sub-region of MENA; and between sub-population groups within each country. The study
will provide empirical evidence necessary for researchers, policy-makers, and public health stakeholders to set research,
policy, and programming priorities for HCV prevention, control, and treatment.
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Background
Despite recent progress in hepatitis C virus (HCV) drug-
related research [1,2], HCV remains a serious public
health issue, with no vaccination yet available [3]. The
estimated prevalence of HCV infection worldwide is 2.8%
[4]. Region-specific estimates range from <1.0% in north-
ern Europe [5] to >3.0% in North Africa [4,6]. The largest
population-level prevalence of HCV infection in the world
is found in Egypt with 14.7% of the adult population being
exposed to the infection [7,8]. Iatrogenic HCV trans-
mission through unsafe (therapeutic) injections, among
other parenteral exposures, has sustained transmission
of the infection in different countries in earlier decades
[9,10] and appears to persist in some of the low-income
countries [11,12].
The aim of this study is to provide a systematic review
and synthesis of all epidemiological data on HCV preva-
lence and incidence among the different population groups
in the Horn of Africa sub-region of the Middle East and
North Africa (MENA) including Djibouti, Somalia, and
Sudan in addition to Yemen at the southwest corner of the
Arabian Peninsula. A second aim of the study is to esti-
mate the national population-level HCV prevalence for
each of these four countries. The combined population of
this sub-region is approximately 85 million, or over
one-fifth of the population of MENA [13]. This MENA
sub-region shares socio-cultural and socio-economic
similarities and geographic proximity that warrant cov-
ering it within the context of one study.
The proposed review is part of a larger project, the MENA
HCV Synthesis Project, an ongoing effort to characterize
HCV epidemiology in all 23 countries of the MENA region.
The ultimate goal of this project is to provide the empirical
evidence necessary for researchers, policy-makers, and pub-
lic health stakeholders to set research, policy, and program-
ming priorities for HCV prevention, control, and treatment
in the MENA region.
Methods
Data sources and search strategy
The review will be conducted based on the items out-
lined in the PRISMA statement [14]. PubMed, Embase,
and the World Health Organization (WHO) regional da-
tabases (WHO African Index Medicus [15] and WHO
Index Medicus for the Eastern Mediterranean Region
[16]) will be searched for eligible studies with no lan-
guage or date restrictions. MeSH, Emtree, and free-text
terms grouped in two categories will be used: hepatitis C
and location (Africa and Yemen). The Boolean operators
“AND” will combine the categories and “OR” will join
the terms within each category, respectively. Search terms
and keywords will be altered as per specification of individ-
ual databases. To ensure that we will identify all relevant
articles, the search for the African countries (Djibouti,
Somalia, and Sudan) will cover the whole African con-
tinent, and we will select manually the relevant arti-
cles. Yemen is technically in Asia and therefore will be
included explicitly in the search terms. In addition, the
search will incorporate spelling and acronym variants
(for example: VHC, HVC, hépatite) and nationality adjec-
tive (for example: African and Yemeni). Specific search
criteria are provided in Additional file 1.
The database searches will be supplemented by search-
ing through citations and references of all included pa-
pers and identified reviews. Additional sources will be
obtained through the database of the MENA HIV/AIDS
Epidemiology Synthesis Project [17,18], including inter-
national organizations’ reports and country-level reports,
and abstracts of international conferences, and by con-
tacting authors.
Inclusion and exclusion criteria
Studies will be considered eligible for inclusion in the
proposed review if they are performed in one of the four
countries of interest: Djibouti, Somalia, Sudan, and Yemen.
Eligible studies must include data on the number or fre-
quency (sero-prevalence and/or sero-incidence) of individ-
uals exposed to HCV in any given population at a specific
time or for a given period of time. Only studies referring
explicitly to HCV and published after the discovery of
HCV in 1989 will be considered for the review. Studies re-
ferring to HCV as non-A non-B hepatitis will be excluded.
We will include observational and intervention studies
with primary data using cross-sectional, case–control,
and cohort (prospective and retrospective) designs. For
case–control studies of different conditions, we will ex-
tract HCV prevalence among cases and controls separ-
ately if available. For cohort studies, we will extract HCV
incidence and/or HCV prevalence (but only at baseline
for prevalence). For intervention studies, we will extract
HCV incidence and/or HCV prevalence (but only at base-
line for prevalence) for the intervention and control arms
separately if available. Case reports, case series, reviews,
qualitative studies, editorials, commentaries, letters to edi-
tors, author replies, and animal studies will be excluded.
In addition, any study with fewer than 15 participants will
not be included.
Studies may be conducted in a variety of settings (such
as clinics, hospitals, households, communities, etc.) and
in any population group. Both sexes and all age groups
from any racial or ethnic population will be included.
Exposure to HCV infection must be ascertained using a
clearly specified laboratory test. Studies using self-report
to identify HCV status will be excluded from the review.
Screening strategy
All citations obtained using the search strategy will be
imported into Endnote (Endnote X7, Thomson Reuters,
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San Francisco, CA), and duplicates will be deleted. The
remaining unique and potentially relevant records will
be imported into Microsoft Excel where screening for
relevance and eligibility will take place. The titles and
abstracts of all retrieved records will be screened for
relevance by Karima Chaabna (KC). Full text of all arti-
cles deemed relevant after the initial title and abstract
screening will be retrieved and assessed for eligibility by
KC. Any remaining non-eligible articles will be excluded.
Reasons for exclusion will be recorded.
Data extraction
Relevant data will be extracted by one reviewer (KC)
from eligible publications into a predefined extraction
Excel sheet developed for this review. All extracted data
will be checked by a second reviewer (Silva Kouyoum-
jian; SK) to assess and ensure the quality of extraction.
The checking will consist of verifying whether, for each
study, all extracted variables are correctly included in the
database. Inconsistencies between reviewers will be dis-
cussed among the study team and sorted out by consensus.
The following data will be extracted from each eligible
study included in the review: author(s), year of publica-
tion, title, journal, study location, year(s) of data collection,
study design, sampling technique, population profile (such
as blood donors, barbers, health care workers, people who
inject drugs), and socio-demographic characteristics of the
population (sex and age). Furthermore, we will extract the
name of the serological test used to determine HCV ex-
posure, the number of participants included and that did
participate, the response rate, and the raw results obtained
for the primary outcome.
Although not part of the inclusion criteria, the following
data will be extracted from included studies when avail-
able: HCV RNA prevalence and incidence, HCV genotype
frequency measures among HCV antibody positive pa-
tients, and risk factors for HCV infection with significant
unadjusted and adjusted odds ratio (p-value ≤ 0.05).
Relevant data will be extracted from abstracts for studies
whose full text could not be obtained even after contact-
ing the authors. Data from any article providing multiple
HCV measures for different population subgroups, sex,
and/or several study periods will be extracted as several
studies and treated as separate datasets in the analysis.
Risk of bias and quality assessment
We will incorporate risk of bias assessment into our
analyses by evaluating sources of bias that may affect the
overall estimations. The methodology for the quality as-
sessment will be adapted from that used recently by two
of the co-authors in a systematic review and data syn-
thesis of HIV prevalence and incidence among people
who inject drugs in MENA [19]. Based on the Cochrane
approach [20], each HCV prevalence measure extracted
will be classified as having a low, high, or unknown risk
of bias in three domains: sampling methodology, HCV as-
certainment, and response rate. Low risk of bias in these
domains will be respectively defined as 1) probability-
based sampling, 2) biological assays, and 3) response
rate ≥80% of the target sample size.
A minimum simple size will be calculated to differenti-
ate estimates with good precision. The minimum sample
size will be calculated using the pooled estimate of HCV
prevalence among the general population in the included
countries [21]. This calculation will utilize the exact bino-
mial (Clopper-Pearson) confidence interval formula [21].
Studies classified as “with good precision” should have a
sample size equal to or higher than this calculated mini-
mum sample size. Small-study effect on the effect size will
be explored by the use of funnel plots [22], and asymmetry
will be tested using Egger’s test [23]. Sensitivity analysis re-
stricted to studies at low risk of bias will be performed.
Ethics statement
Our review will not require an ethics committee ap-
proval or written informed consent because it relies en-
tirely on published data.
Data synthesis
We will calculate 95% confidence intervals for all HCV
prevalence measures with the Clopper-Pearson method
[21,24]. The data will be synthesized by country and by
study population for HCV exposure. Four population
groups are defined for this study: (1) high risk groups
(such as hemodialysis patients and people who inject
drugs); (2) intermediate risk groups (such as healthcare
workers, prisoners, barbers, and children and spouses of
index patients); (3) general population groups which repre-
sent the low risk groups (such as blood donors, pregnant
women, and healthy populations); and (4) special clinical
groups (such as patients with non-Hodgkin lymphoma
(NHL), hepatocellular carcinoma (HCC), and chronic and
acute viral hepatitis, among other populations where the
risk of exposure to HCV infection is uncertain).
Data analysis
In the framework of the current systematic review, we
plan to estimate pooled HCV prevalence and incidence
by population subgroup (high risk population, inter-
mediate risk population general population, and special
clinical population) in each country included in our ana-
lysis. Inverse-variance weighted random-effects models will
be used following the conventional method of DerSimonian
and Laird [25] after stabilizing the variance by trans-
forming the proportions using the Freeman-Tukey
double-arcsine method [26]. The back-transformed
pooled proportions will be calculated using Miller’s inverse
transformation with the harmonic mean of the sample sizes
Chaabna et al. Systematic Reviews 2014, 3:146 Page 3 of 5
http://www.systematicreviewsjournal.com/content/3/1/146
[27]. The value 0.5 will be added to all cell frequencies of
studies with a zero cell count [28]. Forest plots will be
generated displaying prevalence (or incidence) with the
corresponding 95% confidence intervals for each study
and the overall random-effects pooled estimate with its
confidence interval [29].
To identify heterogeneity between studies, we will
visually inspect the Forest plots, perform Cochran’s Q test
[30], and estimate the between-study variance of the true
effect sizes (τ2) using the DerSimonian and Laird method
[25,31]. To examine the magnitude of the variation be-
tween studies due to heterogeneity rather than chance,
and whether it impacts the conclusions of the meta-
analyses, we will quantify the heterogeneity by using
the I2 measure and its confidence interval [32]. We will
consider a two-sided probability value <0.10 as significant.
A meta-regression will be conducted to identify sources
of between-study heterogeneity in the pooled prevalence
(or incidence) estimates [33]. Several potential sources of
heterogeneity will be specified a priori. The factors consid-
ered will be those related to the characteristics of studies
(such as risk of bias and year of publication); or sub-
populations (such as blood donors and pregnant women).
A multivariate meta-regression model will be built by add-
ing each variable sequentially starting with the variable
that shows the strongest association with HCV prevalence
(or incidence) in a univariate analysis. A variable will re-
main in the multivariate model if it will be independently
associated with HCV prevalence at p ≤ 0.10.
Statistical analyses will be performed with Stata v.13.1
(StataCorp, College Station, TX, USA) and R v. 3.1.1.
Discussion
This systematic review and meta-analysis will define the
distribution of HCV prevalence and incidence across
countries in the Horn of Africa sub-region of MENA
including Djibouti, Somalia, Sudan, and Yemen; and be-
tween sub-population groups within each country. The
rigorous systematic review and meta-analysis method-
ology used in this study will ensure a robust knowledge
synthesis of available data. The study will provide empir-
ical evidence necessary for researchers, policy-makers
and public health stakeholders to set research, policy
and programming priorities for HCV prevention, con-
trol, and treatment in MENA.
Additional file
Additional file 1: Search criteria. Search terms for PubMed and
Embase electronic databases.
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